NewcelX Appoints Dr. Julien Boisdron to Scientific Advisory Board
NewcelX Ltd. (NASDAQ: NCEL) is making strides in diabetes innovation with the recent appointment of Dr. Julien Boisdron to its Scientific Advisory Board (SAB). Dr. Boisdron, a distinguished expert in diabetes care, has a rich history of leadership within the pharmaceutical sector, specifically focusing on diabetes technologies and strategies.
Dr. Boisdron’s Extensive Experience
With over two decades of global experience in diabetes management, Dr. Boisdron currently holds the position of Chief Medical Officer for a leading Swiss-based pharmaceutical company. In this role, he is responsible for the strategic direction of advanced diabetes technologies and clinical initiatives. His expertise particularly shines in the development of innovative insulin-management systems and integrated digital healthcare solutions aimed at optimizing patient outcomes.
Contributions to NewcelX’s IsletRx Program
Dr. Boisdron's role at NewcelX is pivotal, as he will guide the company’s lead therapeutic program, IsletRx, which is focused on stem-cell-derived treatments for insulin-dependent Type 1 Diabetes. This condition is a primary focus area for NewcelX, and Dr. Boisdron’s insights will be valuable as they navigate the path towards clinical trials.
Commitment to Innovation
Speaking on his new position, Dr. Boisdron expressed his enthusiasm by stating, "I am honored to join NewCelX's Scientific Advisory Board and to collaborate on advancing next-generation therapies for diabetes. The company's innovative platform is a remarkable base to push forward transformative treatment options for patients." His input will shape the translational strategy to enhance patient adoption, integration into healthcare systems, and future commercialization efforts.
NewcelX's Vision and Leadership Support
Prof. Michel Revel, NewcelX's Chief Scientific Officer, stated that welcoming Dr. Boisdron represents a significant boost to their leadership in metabolic and regenerative medicine. His vast experience is anticipated to enrich the strategic pathways as NewcelX advances its IsletRx program.
Ronen Twito, Executive Chairman & CEO, emphasized that Type 1 Diabetes is crucial to the company's clinical strategy and that Dr. Boisdron's background will greatly enhance their approach to developing a cell-based therapy tailored to individual patient needs.
About NewcelX Ltd.
NewcelX Ltd. (NASDAQ: NCEL) is at the forefront of biotechnology, focusing on innovative cell-based and small-molecule therapies designed to address neurodegenerative and metabolic diseases. They employ a unique integrated platform that combines advanced stem-cell technologies with neuroscience to create scalable treatments targeting conditions such as ALS and Type 1 Diabetes. The company operates out of Zurich, Switzerland, with dedicated research and development activities in Ness Ziona, Israel.
Social media engagement remains strong for NewcelX, allowing investors and interested parties to stay connected through platforms like LinkedIn and Facebook.
Frequently Asked Questions
What is NewcelX Ltd. focused on?
NewcelX Ltd. specializes in developing innovative therapies for neurodegenerative and metabolic diseases, particularly Type 1 Diabetes.
Who is Dr. Julien Boisdron?
Dr. Julien Boisdron is an expert in diabetes management, with extensive leadership experience in the pharmaceutical industry.
What is the significance of the IsletRx program?
The IsletRx program aims to develop stem-cell-derived therapies for insulin-dependent Type 1 Diabetes, focusing on improving patient outcomes.
How will Dr. Boisdron contribute to NewcelX?
Dr. Boisdron will provide strategic guidance for the IsletRx program, helping navigate clinical trials and commercialization processes.
Where is NewcelX located?
NewcelX is headquartered in Zurich, Switzerland, with research and development facilities in Ness Ziona, Israel.
